OS benefit with durvalumab in NSCLC holds long term

  • Gray JE & al.
  • J Thorac Oncol
  • 14 Oct 2019

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Long-term OS with durvalumab after chemoradiotherapy (CRT) for stage III unresectable NSCLC was significantly better than with placebo, with nearly 60% of patients alive at 3 years posttreatment.

Why this matters

  • Initial results from phase 3 PACIFIC trial led to the approval of durvalumab for the treatment of unresectable stage III NSCLC without progression on CRT.

Study design

  • Long-term outcomes from the randomized, phase 3 PACIFIC trial.
  • 709 patients with stage III unresectable NSCLC and no progression after CRT received durvalumab (n=473) or placebo (n=236).
  • Median follow-up, 33.3 months.
  • Funding: AstraZeneca.

Key results

  • Durvalumab was associated with a significant decrease in mortality risk (HR, 0.69; 95% CI, 0.55-0.86).
  • Better OS with durvalumab vs placebo at 12 months (83.1% vs 74.6%), 24 months (66.3% vs 55.3%), and 36 months (57.0% vs 43.5%).
  • Durvalumab was associated with longer time to first subsequent therapy or death (HR, 0.58; 95% CI, 0.47-0.71) and time to second subsequent therapy or death (HR, 0.61; 95% CI, 0.49-0.75).

Limitations

  • Programmed death-ligand 1 expression not available in some patients.